Transgenomic, Inc. (TBIO) Announces Issuance Of New European Patent Covering COLD-PCR Technologies
7/31/2014 11:26:36 AM
OMAHA, Neb.--(BUSINESS WIRE)--Transgenomic, Inc. (NASDAQ: TBIO), a global biotechnology company advancing personalized medicine in cardiology, oncology, and inherited diseases through advanced diagnostic tests and clinical and research services, today announced that the European Patent Office has issued a new patent, European Patent No. 21833798, covering one of its COLD-PCR family of DNA amplification technologies. The patent covers Full COLD-PCR, a foundation for the company’s highly sensitive ICE COLD-PCR technology. The COLD-PCR technology is owned by the Dana-Farber Cancer Institute, Boston USA, and exclusively licensed to Transgenomic.
Help employers find you! Check out all the jobs and post your resume.
comments powered by